SoftBank has contributed to a $350m private placement supporting the health screening provider's reverse takeover.

US-based health information provider Sema4 has completed a reverse merger with special purpose acquisition company CM Life Sciences backed by financing from investors including telecommunications and internet group SoftBank. The combined business is now trading its common stock and warrants on the Nasdaq Global Select Market under the ticker symbols SMFR and SMFRW respectively. CM…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.